Over the past 5 yea rs, work has progressed on the developm ent of a topi eal qu inolone/steroid com bination for the treatment of pa tients wit h acute oti tis media with ty mpa nosto my tubes (A OMT) and patient s with acute otitis externa (AOE) . Th e components of this otic suspensio n are ciprofloxacin 0.3% and dexam eth asone 0.1%.
Over the past 5 yea rs, work has progressed on the developm ent of a topi eal qu inolone/steroid com bination for the treatment of pa tients wit h acute oti tis media with ty mpa nosto my tubes (A OMT) and patient s with acute otitis externa (AOE) . Th e components of this otic suspensio n are ciprofloxacin 0.3% and dexam eth asone 0.1%.
At the tim e of publicati on of this supplement, the New Dru g Application (NDA) for ciproflo xac in/dexamethasone steriIe otic suspe nsio n was under review by the federal Food and Dru g Adm inistration (FDA) . A decision on FDA appro val for the indi cations of AOMT and AOE was ex pec ted on or before July 25, 2003 . Thi s articl e summar izes the result s of several ea rly-and late-p hase studies that suppor t the NDA.
NOA studies
Th e result s of six studies totaling 2,783 patients we re included in the NDA for ciprofloxaci n/dex amethaso ne otic suspe nsion, whic h was accepted by the FD A in Novemb er 2002 :
Safety/pharmacokinetics. A safety study of 606 patient s found no skin sensitization with eitherciprofloxacin/ dexamethaso ne otic or single-age nt ciprofloxacin ophthalmi c sol utio n. A pharmacoki netic study in II of these patient s found that the adm inistration of top ieal ciprofloxacin/dexa methasone res ulted in a 7-fold lower serum dexamethaso ne level tha n did administration of 0.5 mg of ora l dexam ethasone and a 640-fo ld lower seru m level of ciprofloxac in than did 25 0 mg of oral cipro floxaci n.
A OM T illdicatioll. T wo studies with a co mbined population of 800 pat ient s were per for med to test the co mbination drug' s efficacy in AOMT. In one, ciprofloxac in/ dexameth asone was comp ared with cipro floxac in alone to assess the contribution of the dexame thaso ne component. Th e time to cessation of otorrhea was sig nifica ntly sho rter among pat ient s who received the com bination produ ct. In the other study , which included almost 600 patient s, ciprofloxac in/dexamethaso ne was superior to ofloxacin otic solutio n with respeet to all measured endpoints, including clinica l cur e, tim e to cessation of otorrhea , and microb iologic erad ication. Th e presence of the stero id was also fo und to have a significa nt effec t on 2 • Volume 82 • Suppl 2 reso lution of granulation tissue present at baselin e.
A OE indication. Two trials of a com bine d 1,377 patients were conducted for the AOE indication . Th e first, a three-arm study in 909 patient s, found that ciprofloxaci n/ dexameth asone was not inferior to either cipro floxac in or neomycin/polymyxin B/h yd roc ort isone (NPH) with respect to clin ical cure and microbi ologic eradic atio n. The seco nd study , which incl uded 468 patient s, showed that ciprofloxacin/dexamethaso ne treatment result ed in higher clinical and microbi ologic cure rates than did trea tment with NPH.
Phase I and II studies
Pharm acokinetics, safety, and efficacy in AOMT were assessed in two early-phase studies:
Pharmacokinetics. In a rando mized, controlled, doubl eblind, phase I/II study, cipro floxaci n/dexa methaso ne otic was co rnpare d with cipro floxac in ophthalm ic in II patient s, age d I to 12 years, who were undergoin g surg ica l incis ion for the place ment of tymp anostomy tub es. Patient s in both groups recei ved a sing le dose of 4 or 5 drop s in each ear immediately followi ng tube inse rtio n. Se rum level s of ciprofloxaci n and dexameth asone were measured six tim es over a 6-ho ur period. Maximum co nce ntrati on s of ciprofloxacin and dexameth asone were 1.55 and 0.86 ng/mI, respecti vely. The respecti ve half-life of eac h dru g was 2.9 and 2.8 hour s. To assess bioava ilab ility, the otic solution was co rnpa red with a 0.5-mg ora l formulation of dexameth asone. Serum dexamethaso ne levels we re appro xima tely 7-fold lower with the dro ps. Th is finding indica tes that any suppression of the hypoth alam ic-pituitary-adren al ax is is likely to be low and very reversible foll owing twice-dail y treatment for 7 days with cipro floxac in/dexamethaso ne otic suspe nsion.
A OM T indication. A randomized , contro lled, doubleblind co ntribution-of-e lements trial was co nd ucted in approx imately2 00 patients with AOMTat 18 sites throughout the United States. I Patients received 3 drop s of either ciprofloxacin/dexa methaso ne or ciprofloxacin alone twice daily for 7 days. Th e med ian tim e to cessation of otorrhe a was 4 days with the co mbinatio n pro duct and 5 days with the sing le age nt. Thi s difference is both sta tistic ally sig - nifica nt and clinicall y meaningful. Althoug h ciprotloxac in alon e was effec tive, the additi on of dexam eth ason e made treatment more effective because it led to the earlier resolution of intlammation. At the test-o f-cure visit (approxim atel y day 14), clinica l c urerates were 94 % with the co mb ina tio n and 98 % with the single agent; the co rrespo nding mi cr ob iologi c success ra tes were 94 and 93 % . O f parti cul ar note is the fact tha t clinica l cure rat es at days 3 and 8 were sig nificantly h igh er in the combination group. Treatment fa ilur e rates were low er in pati ents treated wi th the steroid product.
Phase III studies
On e phase III study for the AO MT indi cati on and tw o fo r the AOE indi cation we re co nduc ted:
AOMT indication. Ciprotloxacin/dexameth aso ne was co mpared with otloxaci n otic so lutio n in 599 pat ient s at 40 sites in the Uni ted States and Can ada. (O tloxacin is already indicated fo r the treatment of AOMT, AOE, and chron ic suppurative otitis med ia. ) Ciprotloxacin/dexameth asone was admi nis te red at 4 drops twi ce a da y for 7 days, and otl oxaci n was given at its ind icat ed dosage , whic h is 5 drops twice a day fo r 10 day s. M icr ob iol ogic da ta wer e based on swabs taken prior to treatment. A second swab wa s obtai ned only ifther e was ei the r a treatm ent fa ilure or so me other reason to discontinue therapy. No second swa bs were taken fro m patients who had alr ead y shown a cl ean , dry ear by the end of the tri al. All ears we re clean ed pri or to treatment-most with su ctio n but a few with dr y swabs . Sp ecim en s we re obtain ed fro m the lumen of the tym pan ostom y tub e, and ca re was taken no t to tou ch the wa lls of the ex terna l ea r canal.
Pati ents we re evalu ated on day 1 (baseline), day 3, day II (end of ther apy ), and da y 18 (tes t-of-cure). Th e median time to cessation of otarrhea was 4 days in the ciprotloxacin/d exam eth ason e grou p and 6 days in the otloxaci n group-a sign ifica nt differen ce both sta tis ti-cally and clinica lly (table I) . Clinica l cure ra tes on day 18 were 90 and 79%, res pec tive ly, and the corres po ndi ng micro bio logic cure rates we re 9 1 and 82 %.2Fai lure rates we re 5 and 15%, resp ect ively. Th e differ ences in all of these rates are also clinicall y and statistica lly sig nifica nt.
Granulation tissue was present in 90 pati ent s, a sa mp le that was large enough to allow for therapeuti c co mpar iso ns . Again, the co mbinatio n product was sig nifica ntly more effec tive than otl ox aci n in treatin g gra nulatio n tissu e at days II and 18; the differ en ce at day 3 was not sta tis tica lly significant, but it was clearly in favo r of ci pro floxac in/dexamet hasone. ' In terms of all other measured endpo ints , ciprotl oxacin/dexameth ason e was superior to otloxaci n.
Both tre at rnents were safe and we il toler ated ; adverse events we re mild to mod erat e and usu all y reso lved without int er vent ion. No clinicall y or statistically sig nificant differen ces we re obse rve d in the mean cha nge in speech reception thresh old in the two groups . Bone-and airco nduc tio n audiometry detect ed no clinically relevant decr ease in hearing from basel ine in eithe r gro up. AOE indleatian. Of the tw o phase III studies for the AO E indication, one was a two-arm study and the other was a three-arm trial.
In the two -arm study, ciprotloxacin/dexamethasone was compared with NPH in 46 8 pat ients at 23 sites in the United Sta tes .' In the ci protloxacin/dexame thasone gro up, ch ildren receive d 3 drop s twice dail y fo r 7 days and adults 4 dro ps; chi ld ren and ad ults in the NPH gro up fo llo wed the sa me regim en except that they were dosed th ree times dail y. Patients were assessed at day I , day 3, day 8, and at the test-of-cure visit on day 18. Cl ini cal cure rates we re 92 % in the ci protloxaci n/dexame thasone gro up and 89 % in the NPH gro up; microb iol ogic success rates we re 92 and 85%, res pe ctive ly ; and the corresp on ding intlammation reductio n ra tes we re 90 and 8 1% (table 2) . Th e qu inol one/ steroid co mbin atio n also pro vided a high er ra te of eradicati on of Pseudotnonas aeruginosa. sone otic , ciprot1o xacin ophthalmic, or NPH . ClinicaI cure rates and microbiologic success rates in the two ciprot1o xacin groups were marginalIy high er than those in the NPH group. Th e median time to the end of pain was 5 days in all three groups. All agents wer e weIl tolerated and side effects were minimaI.
